Legacy Healthcare, a privately held Swiss biopharmaceutical company developing botanical prescription medicines, announced on October 13, 2026, that the United States Food and Drug Administration has granted Breakthrough Therapy designation to CINAINU (LH-8), its investigational topical solution for moderate-to-severe alopecia areata in adults, adolescents and children aged two years and older. The designation follows positive findings from the company’s randomized RAAINBOW Phase 2/3 study, which investigated hair regrowth and tolerability in 107 children and adolescents.
The regulatory decision is significant because the existing United States treatment landscape includes oral Janus kinase inhibitors for severe alopecia areata, while approved options remain limited for patients with moderate disease and children younger than 12. CINAINU is being developed as a topical alternative intended to address a broader range of disease severity and ages. However, Breakthrough Therapy designation is not marketing approval, and the product remains investigational.
The clinical evidence supporting the designation requires careful interpretation. Although RAAINBOW randomized 107 pediatric participants, its prespecified primary efficacy analysis included 62 patients who met additional disease-severity confirmation criteria. Within that population, CINAINU demonstrated a statistically significant advantage over placebo on the primary scalp hair-loss measure at Week 24, with an adjusted difference of 26.3 percentage points and a p-value of 0.0488.
Legacy Healthcare is preparing a larger multinational Phase 3 study, RAAINBOW-2, expected to enroll at least 500 participants across pediatric and adult age groups. That programme will test whether the earlier findings can be reproduced in a broader population and whether the company’s proposed topical treatment can offer meaningful benefits without the systemic risks associated with certain existing medicines.
What does FDA Breakthrough Therapy designation mean for CINAINU’s development?
FDA Breakthrough Therapy designation is intended for investigational treatments addressing serious or life-threatening conditions when preliminary clinical evidence indicates the possibility of substantial improvement over available therapy on a clinically significant endpoint. The programme can provide opportunities for more intensive interaction with FDA reviewers and organizational support during development. It can also make a medicine eligible for certain expedited regulatory mechanisms when the relevant criteria are met.
The designation does not establish that the FDA has independently confirmed the treatment’s clinical superiority or determined that its existing evidence is sufficient for approval. Those conclusions require a complete assessment of the clinical, manufacturing and safety data supporting a marketing application. CINAINU must therefore successfully complete additional development before it can be prescribed as an approved treatment for alopecia areata.
An important feature of the announcement is the designated population. Legacy Healthcare says the designation covers adults, adolescents and children aged two years and older with moderate-to-severe disease. The principal published randomized efficacy evidence, however, comes from patients aged two to 17 years, meaning the forthcoming development programme must also address the proposed adult population.
The company describes CINAINU as the first FDA-regulated multi-plant botanical drug candidate to receive Breakthrough Therapy designation. That classification reflects the botanical nature of the investigational formulation and its development through the prescription medicine framework. It does not make the product a dietary supplement or mean that botanical ingredients are exempt from conventional drug approval requirements.
What did the 107-patient RAAINBOW trial establish about scalp hair regrowth?
RAAINBOW was an international, randomized, double-blind, placebo-controlled Phase 2/3 trial conducted at 12 sites across Bulgaria, France, Germany and India. It enrolled 107 children and adolescents aged two to 17 years with alopecia areata and allocated participants in a two-to-one ratio to receive CINAINU or placebo. Treatment was applied to the entire scalp twice daily for 24 weeks, followed by 24 weeks of observation without the investigational treatment.
The primary endpoint measured relative change in the Severity of Alopecia Tool score, commonly known as SALT, from baseline to Week 24. SALT estimates the percentage of scalp affected by hair loss, with higher scores indicating more extensive hair loss. A reduction in SALT therefore represents improvement in scalp hair coverage.
The published analysis showed an adjusted mean difference of 26.3 percentage points favoring CINAINU, with a 95% confidence interval of 0.1 to 52.5 percentage points. The p-value was 0.0488, narrowly meeting the conventional statistical significance threshold of 0.05. The reported standardized effect size, Cohen’s d, was 0.52, suggesting a moderate treatment effect within the analyzed population.
The responder analysis provided another measure of benefit. At Week 24, 26.2% of CINAINU recipients achieved at least a 40% relative improvement in their SALT score, compared with 5.0% receiving placebo. The reported p-value was 0.0484, again demonstrating a statistically significant but borderline result.
These findings support evidence of treatment activity, but the size of the confidence interval indicates substantial uncertainty about the precise magnitude of the effect. The trial also did not demonstrate a statistically significant difference in absolute SALT score change at Week 24, where the reported p-value was approximately 0.08. That distinction matters because relative improvement and absolute hair coverage can communicate different aspects of clinical benefit.
Why were only 62 patients included in the primary efficacy analysis?
The most important methodological limitation concerns the difference between the randomized population and the full analysis set used for the primary efficacy assessment. RAAINBOW randomized 71 patients to CINAINU and 36 to placebo, but the primary analysis included 42 and 20 participants, respectively. This meant that 45 randomized patients were excluded from the principal analysis population.
The study protocol required participants in the primary analysis to have confirmed moderate-to-severe alopecia areata, defined by a SALT score between 25 and 95 at randomization. Eligibility was determined using assessments from both investigators and independent expert reviewers. Some patients initially assessed as eligible during screening no longer satisfied the required thresholds or had differences between the two assessments.
The investigators reported that eight exclusions reflected changes in disease severity between screening and randomization, while 37 involved disagreement between investigator and expert assessments about whether the patient fell within the specified severity range. The researchers stated that the primary analysis population had been defined before treatment assignments were unblinded. This distinction is important because a prespecified analysis is methodologically different from selecting a favorable subgroup after reviewing results.
Nevertheless, excluding more than 40% of randomized participants creates a substantial interpretive challenge. It reduces the effective population supporting the primary finding and raises questions about how consistently the results would apply across the wider intended treatment population. Independent dermatology commentary published alongside the research highlighted the importance of this population selection issue.
The company and investigators have defended the analytical approach on the grounds that it focused on the intended disease-severity range and preserved treatment allocation within the selected population. However, the larger Phase 3 programme will need to demonstrate that the benefit remains robust under a clear and consistently applied analysis strategy.
How meaningful was the hair regrowth observed after treatment stopped?
One potentially interesting finding was the persistence of a treatment advantage after the initial 24-week treatment period ended. At Week 48, the adjusted difference in relative SALT score change favored CINAINU by 39.4 percentage points, with a 95% confidence interval of 13.1 to 65.6 percentage points. The reported p-value was 0.0033 within the relevant analysis.
The study also found that 47.6% of CINAINU-treated patients in the evaluated population achieved a SALT score of 20 or lower at Week 48, compared with 15.0% in the placebo group. A SALT score of 20 corresponds to 20% or less scalp hair loss, a threshold frequently used in alopecia areata research. These findings suggest that some patients maintained or continued gaining hair coverage after the planned treatment period.
However, the Week 48 analysis involved fewer patients than the original randomized population. Missing follow-up measurements and differences between participants remaining in the analysis may influence the observed results. The study’s own statistical framework also distinguishes prespecified confirmatory endpoints from additional exploratory outcomes.
The findings are scientifically interesting because durability after treatment discontinuation represents a potentially valuable characteristic in a disease prone to recurrence. Oral JAK inhibitor treatment can be followed by renewed hair loss after discontinuation, making sustained responses an important treatment objective. Nevertheless, there is no randomized head-to-head study establishing that CINAINU produces more durable remission than an approved JAK inhibitor.
The next trial will need to examine durability prospectively and determine whether the favorable follow-up results occur consistently in a substantially larger population. Treatment-free follow-up may become an important component of the product’s potential differentiation, but the current data are not sufficient to establish a durable disease-modifying effect.
What do the pediatric safety findings suggest about CINAINU’s tolerability?
The published RAAINBOW findings reported that CINAINU was generally well tolerated during the controlled treatment period. Investigators did not identify serious adverse events related to the investigational solution, and most reported adverse events were mild or moderate. The clinical publication also described favorable treatment tolerability during follow-up.
CINAINU contains four botanical extracts and is being developed for local scalp application. Legacy Healthcare has described anti-inflammatory, antioxidant and anti-apoptotic properties identified in earlier research. These proposed activities may help explain its development rationale, but the precise contribution of each extract to observed patient outcomes has not been established by the Phase 2/3 results.
A topical formulation may potentially reduce exposure-related concerns associated with some systemic treatments. However, topical administration does not automatically guarantee the absence of systemic absorption, allergic reactions or other adverse effects. A new prescription medicine requires appropriate assessment of local tolerability, systemic exposure where relevant and safety during repeated administration.
The planned inclusion of children as young as two years makes extended safety evaluation particularly important. Younger children can differ from adolescents and adults in skin characteristics, body size and medication exposure. The final clinical and manufacturing package must support the proposed dosing regimen across the intended age range.
For Legacy Healthcare, the absence of serious treatment-related adverse events in the earlier pediatric trial is supportive. It does not establish that uncommon adverse events can be excluded or that the product is safer than every approved alopecia areata treatment.
Can CINAINU compete with Pfizer’s Litfulo and other approved JAK inhibitors?
The United States market for severe alopecia areata now includes several approved oral JAK inhibitors. Eli Lilly’s Olumiant, containing baricitinib, received FDA approval in June 2022 for adults with severe disease. Pfizer’s Litfulo, containing ritlecitinib, followed in June 2023 for adults and adolescents aged 12 years and older.
Sun Pharmaceutical Industries’ Leqselvi, containing deuruxolitinib, was approved in July 2024 for adults with severe alopecia areata. These medicines have provided additional treatment options for patients experiencing substantial scalp hair loss. However, their authorized populations differ, and none of these approvals establishes an indication covering children younger than 12.
The oral treatments also carry warnings concerning potential serious infections and other important risks associated with JAK inhibition. Appropriate treatment decisions depend on the individual patient’s disease severity, medical history, age and the product’s approved information. The existence of these warnings creates interest in alternative mechanisms, but it does not establish that a topical investigational medicine will provide an equivalent benefit with fewer risks.
CINAINU’s proposed market position differs in two important respects. First, Legacy Healthcare is pursuing patients with moderate as well as severe alopecia areata. Second, the intended age range includes younger children, a population without the same approved systemic treatment options available to older patients.
These distinctions may support a meaningful commercial opportunity if the treatment successfully demonstrates efficacy. However, the broader population has not yet been validated through the proposed pivotal study, and CINAINU has not been directly compared with approved JAK inhibitors. Its competitive value will ultimately depend on the balance of hair regrowth, safety, durability, ease of application and cost.
What must the planned RAAINBOW-2 Phase 3 study demonstrate?
Legacy Healthcare announced in January 2026 that the FDA had cleared its Investigational New Drug application, permitting the company to proceed with an international Phase 3 study known as RAAINBOW-2. The planned programme is designed as a randomized, double-blind, placebo-controlled trial involving at least 500 participants with moderate-to-severe alopecia areata. The intended population includes children, adolescents and adults.
The study represents a substantial increase in planned enrollment compared with the original 107-patient investigation. That expansion is important because it should allow more precise estimation of the treatment effect and a larger safety database. It will also provide an opportunity to assess whether efficacy extends beyond the pediatric population previously studied.
The company has also reported discussions with Japan’s Pharmaceuticals and Medical Devices Agency concerning the proposed international programme. The Japanese authority provided feedback supporting evaluation of adult and pediatric patients within the development strategy. However, regulatory acceptance of a study design is distinct from advance confirmation that a successful trial will automatically result in marketing authorization.
Legacy Healthcare has identified fundraising and partnership development as elements of its broader clinical strategy. The company has not disclosed a completed financing package covering every remaining development expense or a confirmed commercial launch date. The timing of trial initiation, enrollment and eventual regulatory submissions will therefore depend on operational progress.
The most important scientific issue will be whether a larger randomized population confirms the earlier SALT improvement under a prespecified primary analysis. The trial must also establish clinically meaningful responder rates, treatment durability and acceptable safety across the intended age range.
CINAINU’s FDA Breakthrough Therapy designation represents significant regulatory recognition for a topical botanical medicine being developed in an underserved area of dermatology. The earlier pediatric trial provides a legitimate signal of hair-regrowth activity and encouraging tolerability, but its narrow statistical margin and reduced primary analysis population warrant careful interpretation.
The next meaningful milestone is the execution and outcome of RAAINBOW-2. If the larger study reproduces the efficacy signal and supports treatment across the proposed age groups, Legacy Healthcare could pursue a differentiated prescription option for moderate-to-severe alopecia areata. Until then, CINAINU remains investigational, and the designation should be understood as support for further development rather than proof of regulatory or commercial success.
